Samsara Vision Launches PERSPECTIVE Trial, Achieves First Implant of SING IMT in Pseudophakic Patient

Samsara Vision announced the initiation and successful first surgery of the PERSPECTIVE clinical trial. The study will evaluate the safety and efficacy of the Smaller-Incision New-Generation Implantable Miniature Telescope (SING IMT) in pseudophakic patients.

The PERSPECTIVE trial is underway across three CE referenced countries where the SING IMT is already approved for use. Surgeons participating in the study are exploring implantation of the miniature telescope in late-stage AMD patients who have previously undergone cataract surgery with IOL implantation—a population currently contraindicated for the device.

On September 30, 2025, Dr. John Conrath, a vitreoretinal and cataract surgeon at Centre Monticelli-Paradis in Marseille, France, performed the first SING IMT implantation as part of the new trial.

“Implanting the SING IMT in pseudophakic patients is just the beginning—structured visual rehabilitation is critical also for patients to adapt to their new vision,” said Dr. Conrath. “Through PERSPECTIVE, we aim to better understand how surgery and training together can restore meaningful function to patients with late-stage AMD.”

PERSPECTIVE is a multicenter, randomized clinical trial expected to enroll participants through 2026. It is the first study of its kind to assess implantation outcomes in pseudophakic eyes in a controlled, multinational setting.

Primary endpoints will include assessments of safety, visual performance, patient selection criteria, and rehabilitation strategies following implantation.

“Most older adults experience immense benefits from routine cataract surgery with an intraocular lens implant,” said Thomas Ruggia, CEO and president of Samsara Vision. “However, individuals with co-existing AMD who advance to late-stage disease with central vision loss do not experience the same vision benefits from IOLs. Central vision restoration for these patients is a huge unmet medical need. We’re excited to advance the PERSPECTIVE clinical trial to generate meaningful data to inform a possible label expansion so that we can offer our sight-enhancing device to many patients in CE referenced countries.”

To learn more about the PERSPECTIVE clinical trial, visit clinicaltrials.gov/study/NCT07164378.